Fig. 4.

Percentage of patients developing hyperglycaemia (post-baseline FPG ≥ 126 mg/dL or receiving antidiabetic medication post-baseline) during treatment with pasireotide LAR or active control, stratified by baseline FPG levels ≤ 100 or >100 mg/dL, in patients without baseline antidiabetic medication